local_hospital

Centre Hospitalier Universitaire De Nice

Address
lock Available on a paid plan

Immunology and Inflammatory Diseases

The clinical research at Centre Hospitalier Universitaire De Nice includes a strong focus on immune system diseases and chronic inflammatory conditions. Studies are exploring better ways to manage alopecia areata, giant cell arteritis, psoriasis, vitiligo, and hidradenitis suppurativa, with the goal of improving symptom control and long-term disease management.

  • Testing new therapies for autoimmune and skin-related inflammatory disorders
  • Evaluating treatment effectiveness in chronic immune-mediated diseases
  • Improving options for patients with difficult-to-control inflammatory conditions

These trials reflect active work in both dermatology and rheumatology, with an emphasis on finding more effective and better-tolerated treatments.

Gastroenterology and Liver Disease

Research in digestive system diseases is well represented, especially for Crohn's disease, ulcerative colitis, primary biliary cholangitis, hepatic encephalopathy, and NASH/MASH. The studies are designed to assess new treatments that may reduce inflammation, ease symptoms, and slow progression of liver and intestinal disease.

  • Evaluating therapies for inflammatory bowel disease
  • Testing treatments for liver-related complications and chronic liver inflammation
  • Improving disease control and quality of life in long-term gastrointestinal illness

This area highlights an important mix of gastroenterology and hepatology research at the site.

Hematology and Blood Cancers

The site is actively involved in hemic and lymphatic diseases, with trials in acute myeloid leukemia, myelodysplastic syndromes, myelofibrosis, lymphoma, and paroxysmal nocturnal hemoglobinuria. Research here is focused on better treatment strategies for blood cancers and related disorders that affect blood production and immune function.

  • Testing new approaches for leukemia and other hematologic malignancies
  • Assessing treatments that may reduce transfusion needs and improve blood counts
  • Studying therapies for relapsed or hard-to-treat lymphoma

These studies support ongoing advances in hematology and cancer care at Centre Hospitalier Universitaire De Nice.

Oncology and Cancer Immunotherapy

Clinical trials in neoplasms cover a broad range of cancers, including melanoma, biliary tract carcinoma, hepatocellular carcinoma, cutaneous squamous cell carcinoma, basal cell carcinoma, and Wilms tumor. The main aim is to evaluate whether new or combined cancer treatments can improve survival, prevent recurrence, or strengthen disease control after surgery or prior therapy.

  • Testing immunotherapy and targeted treatment strategies in solid tumors
  • Studying adjuvant approaches to reduce cancer recurrence
  • Evaluating options for advanced or difficult-to-treat cancers

This portfolio shows a strong commitment to oncology research, especially in cancer immunotherapy and treatment optimization.

Infectious Diseases and Respiratory Care

Research in bacterial infections, virus diseases, and respiratory tract diseases includes studies in HIV-1 infection, COVID-19, community-acquired pneumonia, and severe pneumonia. These trials aim to improve infection control, refine treatment choices, and support recovery in hospitalized patients.

  • Evaluating antiviral strategies for people living with HIV
  • Testing treatments for COVID-19 and serious respiratory infections
  • Improving antibiotic use and care in pneumonia

The work combines infectious disease and pulmonary medicine research with a practical focus on patient outcomes.

Cardiometabolic and Neurologic Research

Trials in cardiovascular diseases, nutritional and metabolic diseases, and nervous system diseases address conditions such as atherosclerotic cardiovascular disease, obesity, overweight, and migraine. The research is centered on prevention, symptom relief, and better long-term management of common chronic conditions.

  • Studying prevention strategies for cardiovascular risk
  • Testing therapies for obesity-related metabolic disease
  • Exploring improved care for migraine attacks in emergency settings

These studies broaden the site’s work across cardiology, metabolism, and neurology.

Rare and Pediatric Disorders

Some trials focus on congenital, hereditary, and neonatal diseases, including rare conditions such as recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and genodermatoses. Research also includes pediatric studies in alopecia areata and psoriasis, reflecting an interest in conditions that affect children and families.

  • Testing new treatment options for rare inherited skin disorders
  • Evaluating therapies for pediatric immune-mediated diseases
  • Supporting better care for uncommon and severe lifelong conditions

This area highlights the site’s contribution to rare disease and pediatric research in France.

Site Overview

assignment
577
connected trials
corporate_fare
204
sponsors
science
650
IMPs

Activity Indicator

Last 6 months

52
Trials started
-2% vs previous period.
53
Trials started 6–12 months ago
577
Total trials linked
Highly Active
trending_downDeclining-2%
13
10
7
8
7
7
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status

Top 5 of 27 therapeutic areas and 15 of 650 IMPs, ranked by number of trials.

lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years

Top 40 of 599 compounds, ranked by number of trials.

lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
306
Sponsors (total)
204
Active sponsors
137

Sponsor Network

Top 137 by active trials.

lock +136 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

lock +85 more on a paid plan

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 978 other sites in France

description
Trial volume
577
Outperforms 99% of sites
public
Therapeutic diversity
28areas
Outperforms 97% of sites
groups
Sponsor diversity
204sponsors
Outperforms 99% of sites

Therapeutic Area Benchmark — France

Select a therapeutic area to compare against other sites in France.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: France

Market Share

Country: France

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Centre Hospitalier Universitaire De Nice

lock Showing 1 of 577 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
A double-blind, randomized, placebo-controlled, interventional, multicenter, phase III clinical trial to investigate the safety and efficacy of ABCB5-positive mesenchymal stromal cells (ABCB5+ MSCs) on epidermolysis bullosa (EB)Rheacell GmbH & Co. KGPhase IIINot Yet RecruitingJun 2023Jul 2026

IMP list

lock Showing 1 of 650 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Rituximab23Unknown2018-02-022026-07-14

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.